TSE:4519Pharmaceuticals
Discontinued Neuromuscular Trials but Ongoing Obesity Study Could Be A Game Changer For Chugai (TSE:4519)
In March 2026, Chugai Pharmaceutical reported that partner Roche would discontinue clinical development of GYM329 (emugrobart) for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after Phase II/III data showed insufficient functional benefit despite good safety and target engagement.
An important nuance for investors is that while these neuromuscular programs are ending, Roche and Chugai are continuing Phase II development of emugrobart in obesity, where the biological and...